# OnCo record remedy-plan-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/remedy-plan-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "remedy-plan-therapeutics" ;
  schema:name "Remedy Plan Therapeutics"@en ;
  schema:alternateName "Remedy Plan, Inc."@en ;
  schema:description "Remedy Plan Therapeutics develops RPT1G, a medicine that blocks NAMPT, an enzyme cancer cells rely on for energy. It is in an early trial in acute myeloid leukaemia and high-risk myelodysplastic syndromes."@en ;
  schema:url <https://onco.cc/companies/remedy-plan-therapeutics/>, <https://www.remedyplan.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.remedyplan.com/>, <https://www.remedyplan.com/press-releases-1/remedy-plan-therapeutics-announces-multiple-development-and-corporate-milestones-as-first-in-class-hyperbolic-nampt-inhibitor-rpt1g-advances-in-phase-1-dose-escalation-trial-in-amlmds>, <https://clinicaltrials.gov/study/NCT07107126>, <https://clinicaltrials.gov/study/NCT06667765> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds-higher-risk/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/metabolic-therapy/> .